Back to top
more

Assertio (ASRT)

(Real Time Quote from BATS)

$0.77 USD

0.77
97,807

+0.02 (2.12%)

Updated Apr 19, 2024 11:02 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (96 out of 250)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for ASRT

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Assertio Holdings, Inc. [ASRT]

Reports for Purchase

Showing records 1 - 20 ( 113 total )

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 1

03/12/2024

Company Report

Pages: 10

4Q:23 Revenue Beat On Rolvedon Sales; 2024 Sales Guidance Issued

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 2

03/07/2024

Company Report

Pages: 10

Project 4Q:23 Revenue Fell 38% From 4Q:22, Due To The Decline In Indocin Sales From Exclusivity Loss

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 3

01/04/2024

Company Report

Pages: 10

New CEO Announced; Lower Estimates, Reduce Price Target To $3

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 4

12/20/2023

Daily Note

Pages: 4

We are updating our Healthcare coverage to reflect a recent analyst departure and to drop

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 5

11/09/2023

Company Report

Pages: 10

Lower Estimates And Target To $4 (From $7);Expect 2025 Earnings Rebound; Balance Sheet Solid

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 6

11/09/2023

Company Report

Pages: 4

Dropping Coverage

Provider: BWS Financial

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 7

11/09/2023

Daily Note

Pages: 17

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 8

11/09/2023

Company Report

Pages: 6

3Q23 Recap - Hitting the Reset Button; Balance Sheet Helps

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 9

11/06/2023

Daily Note

Pages: 7

Mid-Day Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 10

11/06/2023

Company Report

Pages: 6

Updated Model Pre 3Q23 Results

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 11

11/03/2023

Company Report

Pages: 10

Project 3Q:23 Revenue Jumped 36% As Rolvedon Launch More Than Offset Indocin Decline From Exclusivity Loss; Maintain $7 Price Target

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 12

11/03/2023

Company Report

Pages: 6

Minimizing Indocin, PT $4

Provider: BWS Financial

Analyst: KHORSAND H

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 13

08/07/2023

Company Report

Pages: 11

Analyst Coverage Transition To James Sidoti; Spectrum Deal Complete

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 14

08/04/2023

Daily Note

Pages: 16

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 15

08/04/2023

Company Report

Pages: 6

2Q23 Recap - Still Value Post Indocin Generic

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 16

08/04/2023

Company Report

Pages: 6

Generic Risk Extends Timeline, PT $6

Provider: BWS Financial

Analyst: KHORSAND H

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 17

07/11/2023

Daily Note

Pages: 9

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 18

07/11/2023

Company Report

Pages: 4

The Rolvedon Advantage

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 5.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 19

05/10/2023

Daily Note

Pages: 19

Morning Summary

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Assertio Holdings, Inc.

Industry: Medical - Drugs

Record: 20

05/10/2023

Company Report

Pages: 11

Raise Estimates And Target To $10 (From $8) Following Strong 1Q:23 Results

Provider: Sidoti CSR

Analyst: Research Department

Price: .00

Research Provided by a Third Party